O Kyu Noh1,2, Seung Yeop Oh3, Young Bae Kim4, Kwang Wook Suh5. 1. Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Korea. 2. Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea. 3. Department of Surgery, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon, 443-721, Korea. kgsosy@ajou.ac.kr. 4. Department of Pathology, Ajou University School of Medicine, Suwon, Korea. 5. Department of Surgery, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon, 443-721, Korea.
Abstract
PURPOSE: There is increasing interest in immune function in combination with chemotherapy for cancer treatment. However, the effects of chemotherapy on the human immune system remain to be determined. The aim of this study was to investigate the prognostic impact of lymphocyte and neutrophil counts in colon cancer patients who were treated with curative surgery and adjuvant chemotherapy. METHODS: Two hundred thirty-one patients with colon cancers who underwent curative surgery and FOLFOX adjuvant chemotherapy between November 2005 and December 2011 were included. Oncologic outcomes were analyzed with neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR) before and after chemotherapy. RESULTS: The 5-year DFS rate was lower in colon cancer patients with low lymphocyte count during chemotherapy (61.9 vs. 76.7%, P = 0.026). Cox multivariate analysis demonstrated that low lymphocyte count during chemotherapy was independently associated with poor disease-free survival (HR 1.829; 95% CI 1.096-3.050; P = 0.021) in colon cancer patients who underwent FOLFOX adjuvant chemotherapy. CONCLUSION: Lymphocyte count during chemotherapy is a strong predictor of worse disease-free survival in colon cancer patients who have undergone FOLFOX adjuvant chemotherapy.
PURPOSE: There is increasing interest in immune function in combination with chemotherapy for cancer treatment. However, the effects of chemotherapy on the human immune system remain to be determined. The aim of this study was to investigate the prognostic impact of lymphocyte and neutrophil counts in colon cancerpatients who were treated with curative surgery and adjuvant chemotherapy. METHODS: Two hundred thirty-one patients with colon cancers who underwent curative surgery and FOLFOX adjuvant chemotherapy between November 2005 and December 2011 were included. Oncologic outcomes were analyzed with neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR) before and after chemotherapy. RESULTS: The 5-year DFS rate was lower in colon cancerpatients with low lymphocyte count during chemotherapy (61.9 vs. 76.7%, P = 0.026). Cox multivariate analysis demonstrated that low lymphocyte count during chemotherapy was independently associated with poor disease-free survival (HR 1.829; 95% CI 1.096-3.050; P = 0.021) in colon cancerpatients who underwent FOLFOX adjuvant chemotherapy. CONCLUSION: Lymphocyte count during chemotherapy is a strong predictor of worse disease-free survival in colon cancerpatients who have undergone FOLFOX adjuvant chemotherapy.
Authors: Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701
Authors: Joyce T Tan; Bettina Ernst; William C Kieper; Eric LeRoy; Jonathan Sprent; Charles D Surh Journal: J Exp Med Date: 2002-06-17 Impact factor: 14.307